MedTrace Logo

Adalimumab in Severe and Acute Sciatica

NCT00470509 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2019-04-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether adalimumab (a TNF-alpha inhibitor) is effective in the treatment of severe and acute sciatica.

Conditions

  • Sciatica

Interventions

DRUG

Adalimumab

2 subcutaneous injections on day 0 and 7

DRUG

Placebos

2 subcutaneous injections on day 0 and 7

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Stéphane Genevay, MD · Geneva University Hospital & Swiss Society of Rheumatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-01-31
Completion
2008-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00470509 on ClinicalTrials.gov